Biosimilar Remsima comparable to Remicade in RA crossover study

Published: 2013-11-01 06:59:00

Updated: 2013-11-01 06:59:00

Korean biotechnology company Celltrion presented results of its crossover trial for its biosimilar Remsima (infliximab candidate) at the American College of Rheumatology (ACR) 2013 Conference, which was held in San Diego on October 28-30.

According to Celltrion, results from the crossover study of biosimilar infliximab proven the equivalence of Remsima and the reference product – Johnson & J...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.